G. Walmsley Graham - Aug 8, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Stock symbol: AKRO
Transactions as of: Aug 8, 2023
Transactions value $: $1,051,475
Form type: 4
Date filed: 8/10/2023, 04:46 PM
Previous filing: Aug 1, 2023
Next filing: Dec 18, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Purchase	$1.05M	+25K	+4.35%	$42.06	600K	Aug 8, 2023	See Footnote	F1, F2
holding	AKRO	Common Stock						2.17K	Aug 8, 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $41.8634 to $42.3525, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
F2	The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Content

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $41.8634 to $42.3525, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.